Drug – bio-affecting and body treating compositions – Whole live micro-organism – cell – or virus containing – Animal or plant cell
Patent
1995-06-07
1998-12-15
Naff, David M.
Drug, bio-affecting and body treating compositions
Whole live micro-organism, cell, or virus containing
Animal or plant cell
435325, 435347, 435354, A01N 6300
Patent
active
058492852
ABSTRACT:
The present invention describes a method of treating a disease that results from a deficiency of a biological factor which comprises administering to a mammal Sertoli cells and cells that produce the biological factor. In particular, the present invention describes a method of treating diabetes mellitus by transplanting pancreatic islet of Langerhans cells in conjunction with Sertoli cells to create an immunologically privileged site. A method of creating an immunologically privileged site and providing cell stimulatory factors in a mammal for transplants is further described by the present invention. The present invention further describes a method of creating systemic tolerance to foreign antigens. A method of enhancing the viability, maturation, proliferation of functional capacity of cells in tissue culture is further provided. A pharmaceutical composition comprising Sertoli cells and cells that produce a biological factor is also provided. In addition treatment of an autoimmune disease via the transplantation of Sertoli cells alone into a transplant site other than the testes is disclosed. The dosage amount of Sertoli cells administered ranges from 10.sup.5 to 10.sup.10 cells. Also an in vitro method of accelerating the maturation and increasing the proliferation and functional capacity of proliferating mammalian cells via the co-culturing of the mammalian cells with Sertoli cells is disclosed.
REFERENCES:
Selawry et al., (1988) "Intratesticular Islet Xenograft Survival in Relation to Tissue Cyclosporine Levels", The American Journal of Medical Science, 295(6): 497-502.
Whittington et al., (1991) "Islet Allografts in the Cryptorchid Tests of Spontaneously Diabetic BB/W or dp Raps: Response to Glucose, Glipizide, and Arginine", Endo. 128(6): 2671-2677.
Tze et al., (1990) "Human Islet Xenograft Survival in Diabetics Rats", Transplantation, 43 (3): 502-505.
Korsgren et al., (1993) "Pancreatic Islet Transplantation in the Human", Advances in Nephrology, 22 : 371-387.
Baker et al., (1991) "Studies of Priviledge Sites and Islet Transplantation", Transplantation Proceedings, 23 :(4) 2138-2142.
Cameron et al., (1990) "Successful Islet Abdominal Testis Transplantation Does Not Require Leydig Cell", Transplantation, 50 :(4) 649-653
Groth et al., (1994) "Transplantation of Porcine Fetal Pancreas to Diabetic Patients", Lancet, 344 : 1402-04.
Selawry et al., (1994) "Extended Functional Survival of Abdominal Intratesticular Islet Allografts in Rhesus-Monkeys", Diabetes, 43 : PA162.
Selawry et al., (1989) "Abdominal Intratesticular Islet-Xenograft Survival in Rats", Diabetes, 38 : (1) 220-223.
Soon-Shiong et al., (1993) "Long-Term Reversal of Diabetes by the Injection of Immunoprotected Islets", Proc. Nat'l Acad. Sci. USA, 90 : 5843-5847.
Soon-Shiong et al., (1994) "Insulin Independence in a Type 1 Diabetic Patient After Encapsulated Islet Transplantation", Lancet, 343 : 950-951.
Tze et al., (1992) "Transplantation of Discordant Pig Islet Xenografts in Diabetic Rats", Diabetes Research and Clinical Practice, 15 : 197-204.
Tze et al., (1993) "Diabetic Rabbit Model For Pig Islet Xenotransplantation", Transplantation, 56 :(6) 1348-1352.
Tze et al., (1994) "Prolongation of Pig Islet Xenograft in Rats By Local Immunosupression with FK 506", Transplantation Proceedings, 26:(2) 777-778.
Selawry et al. (1993) "Sertoli Cell-Enriched Fraction in Successful Islet Cell Transplantation", Cell Transplantation, 2 : 123-129.
Selawry, et al. (Nov. 1991) "Production of a Factor, or Factors, Suppressing IL-2 Production and T Cell Proliferation by Sertoli Cell-Enriched Preparations. A Potential Role for Islet Transplantation in an Immunologically Privileged Site", Transplantation 52 (5):846-850.
Oonk, et al. (1988) "Insulin-Like Growth Factor I (IGF-I) Receptors on Sertoli Cells from Immature Rats and Age-Dependent Testicular Binding of IGF-I and Insulin", Molecular and Cellular Endocrinology 55 :33-43.
Whitmore III, et al. (Oct. 1985) "The Role of Germinal Epithelium and Spermatogenesis in the Privileged Survival of Intratesticular Grafts", Journal of Urology 134 (4) :782-786.
Hofmann, et al. (Aug. 1992), Abstract No. 92347475 "Immortalization of Germ Cells and Somatic Testicular Cells Using the SV40 Large T Antigen", Experimental Cell Research 201 (2) :417-435.
Lejeune, et al. (1993), Abstract No. 93:280614 "Enhancement of Testosterone Secretion by Normal Adult Human Leydig Cells b Co-Culture with Enriched Preparations of Normal Adult Human Sertoli Cells", Int. J. Androl. 16 (1):27-34.
Berends, et al. (1991), Abstract No. 92:167853 "Significant Improvement of the Survival of Seminoma Cells in vitro by use of a Rat Sertoli Cell Feeder Layer and Serum-Free Medium", J. Natl. Cancer Inst. 83 (19):1400-1403.
Carreau, et al. (1988), Abstract No. 88:227147 "Stimulation of Adult Rat Leydig Cell Aromatase Activity by a Sertoli Cell Factor", Endocrinology 122 (3):1103-1109.
Naff David M.
Research Corporation Technologies Inc.
Ware Deborah K.
LandOfFree
Autoimmune disease treatment with sertoli cells and in vitro co- does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Autoimmune disease treatment with sertoli cells and in vitro co-, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Autoimmune disease treatment with sertoli cells and in vitro co- will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1455136